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Abstract 
Background: The purpose of this study was to describe the clinical characteristics of bisphosphonate related oste‑
onecrosis of the jaws (BRONJ) in osteoporotic males.
Methods: The medical records of BRONJ patients from 2007 to 2014 were reviewed. The data from only the male 
patients was extracted, and demographic data was collected and biochemical markers were measured.
Results: 11 Patients out of 210 (5 %) being males. Among the 11 patients, the indication of bisphosphonate (BP) was 
osteoporosis in 9 patients, and cancer in two. In one of the osteoporosis patients, osteoporosis was thought to be 
secondary to hypogonadism after testicular tumor resection. Serum c‑terminal telopetide crosslink of type I collagen 
(s‑CTX) values ranged from 60 to 165 pg/mL (mean: 84.6 ± 36.8, median: 70). Serum osteocalcin (s‑OC) ranged from 0 
to 5.06 ng/mL (mean: 1.83 ± 1.66, median: 1.5) and vitamin D ranged from 0 to 11.9 (mean: 5.02 ± 4.92, median: 3.5).
Conclusion: BRONJ can be overlooked in male patients with osteoporosis. Although the incidence of BRONJ in 
males may be low, dentists should also check if their male patients are on osteoporosis treatment since osteoporosis 
in males can be manifested as a secondary disease to hypogonadism.
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Background
Osteoporosis is a substantially under-recognized disease in 
men and often remains untreated in many cases. Osteopo-
rosis is considered to be found mostly in women because 
postmenopausal osteoporosis is the prevailing type of the 
disease. However, about 39  % of new osteoporotic frac-
tures, which are the most frustrating complications of 
osteoporosis, were reported to have occurred in men by 
2000 (Kaufman et al. 2013). The etiology of osteoporosis in 
males can be different from their female counterpart and 
the etiology is often secondary to some conditions.
Considering men have more morbidity and mortality 
after hip bone fractures than women do (Seeman 2002; 
Lambert et al. 2011), the adequate treatment of osteopo-
rosis in men is also crucially important.
Since BRONJ has been well known to have a sexual 
predilection, clinicians and many general dentists usually 
ask only female patients whether they are on BP therapy. 
Therefore, history taking of BP therapy in male patients 
is rarely investigated. Like the current level of awareness 
of osteoporosis in males, BRONJ in males may be under-
estimated. Although the studies on BRONJ are rapidly 
increasing, little is known about BRONJ in males.
Methods
From 2007 to 2014, all male patients that were diagnosed 
with BRONJ were enrolled in this study. BRONJ was diag-
nosed according to the criteria proposed by the American 
Association of Oral and Maxillofacial Surgeons (AAOMS) 
through radiographic and clinical examinations (Rug-
giero et  al. 2014). At risk category and stage 0 were not 
considered in our study. Only Stage 1, 2, 3 patients were 
inspected and grouped. Initial biochemical data were also 
included. The following clinical data were collected: age 
at diagnosis of BRONJ, gender, duration of BP use before 
diagnosis, underlying medical conditions contributing 
to osteoporosis, indications of BP, location and stage of 
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BRONJ lesion, serum c-terminal telopeptide cross-link of 
type I collagen (s-CTX), serum osteocalcin (s-OC).
The study protocol was approved by the institutional 
review board at Kyung Hee University Dental Hospital 
(KHD IRB 1411-2).
Results
The total number of the patients with BRONJ was 210 
and the number of male patients was 11 (5  %). Among 
the patients with BRONJ, the indications of BP were 
osteoporosis in 9 patients, multiple myeloma in one 
and prostate cancer in one respectively. Ten patients 
presented one stage 2 lesion and one patient showed 
a stage 3 lesion (Fig. 1). One patient (No. 3) underwent 
total orchiectomy and chemotherapy because of tes-
ticular malignancy. Biochemical markers were checked 
(s-CTX, s-OC, Vitamin D) at baseline when BRONJ was 
diagnosed. s-CTX values ranged from 60  to  165  pg/mL 
(mean: 84.6 ± 36.8, median: 70). s-OC ranged from 0 to 
5.06 ng/mL (mean: 1.83 ± 1.66, median: 1.5) and vitamin 
Fig. 1 a Exposed necrotic bone surface on the right posterior maxillary region. (flipped from mirror image). b CBCT scan showed necrotic bone 
and heavy mucosal thickening obliterating the maxillary ostium. c Partial maxillectomy was carried out and buccal fat pad was mobilized to close 
the surgical wound. d Three months postoperatively, the wound was uneventfully healed. (flipped from mirror image)
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D ranged from 0 to 11.9 (mean: 5.02 ± 4.92, median: 3.5). 
The clinical data of the 9 BRONJ patients due to osteopo-
rosis etiology are shown in Table 1.
Discussion
Osteoporosis in men has been a commonly overlooked 
etiology; therefore overlooking BRONJ in men, unless 
there are oncologic indications for BP medication, is even 
higher. A recent report from the National Nutritional 
Survey elucidated the level of recognition of osteoporosis 
in males to be 10.6 % and this figure was lower than that 
in females which was 24 % (Society 2014).
Also as many as one in four men over the age of 
50  years will develop at least one osteoporotic fracture 
in their lifetime (Foundation). Osteoporosis in males 
can arise from geriatric reason and may be manifested 
as a secondary disease. Secondary causes for osteoporo-
sis in men are as high as 65 %, while in women are only 
20–40 % (Dy et al. 2011). Secondary osteoporosis can be 
a marker of systemic disease in the patient resulting from 
endocrine diseases such as diabetes mellitus, hyperpar-
athyroidism, male hypogonadism; gastrointestinal dis-
orders such as gastrectomy, celiac disease, inflammatory 
bowel disease; hematologic diseases such as myeloma, 
systemic mastocytosis; rheumatologic diseases such as 
rheumatoid arthritis, ankylosing spondylitis; and other 
reasons such as alcoholism, excessive smoking, and pul-
monary emphysema (Ebeling 2008; Hofbauer et al. 2010). 
In our study, only 9 % of the patients (1 patient out of 11) 
had secondary osteoporosis. The other 8 patients had 
history of hypertension, brain aneurysm, tuberculosis, 
asthma, and rheumatic arthritis, but there was no evi-
dence that these conditions were related to contributing 
into secondary osteoporosis. Untreated osteoporosis can 
trigger osteoporotic fractures leading to life-threaten-
ing conditions and the cumulative mortality rate can be 
higher in men than women (31 vs. 24.1  %) (Yoon et  al. 
2011). The treatment response to oral bisphosphonates 
in male osteoporosis is similar to that observed in post-
menopausal osteoporosis, showing bisphosphonates as 
the choice of treatment for male osteoporosis (Kaufman 
et al. 2013). Because BP is one of the most common ther-
apeutics for osteoporosis in males, such male patients 
may be at risk for BRONJ. BP therapy history taking is 
often neglected in a male patient set to have a surgical 
procedure involving alveolar bone. Even though there 
have been many papers on BRONJ since the first report 
was released, BRONJ in osteoporotic males has been 
rarely reported. Besides the long-term intake of BPs, con-
comitant risk factors can contribute to the development 
of BRONJ lesions. Those risk factors include corticoster-
oid therapy, diabetes, alcohol and smoking (Khosla et al. 
2007). The existence of one or more BRONJ risk factors 
are expected to contribute to the early development of 
BRONJ but these results have yet to be statistically veri-
fied (Otto et al. 2011).
In our data, male BRONJ patients were 5  % of all 
BRONJ cases and only 4.3 % of all cases were BRONJ in 
osteoporotic males. Based on Otto et al. (2011), 36 % of 
their patients were males but this included BRONJ cases 
originating from oncologic use of BPs. Among BRONJ 
from oral BPs, 19 % were males (Otto et al. 2011). Because 
Table 1 Demographic data of the male patients with BRONJ in this study
a Serum c-terminal telopeptide cross-link of type I collagen
b Serum osteocalcin
c Diagnosed with testicular malignancy and underwent orchiectomy and chemotherapy
Mn mandible, Mx maxilla, BP bisphosphonate
Information on s-CTX and osteocalcin testings in this study
CTX; ECLIA, Elecsys β-CrossLaps, Roche Diagnostics, Germany, Ref. range: < 704 pg/mL in males at 50–70 years old. < 854 pg/mL in males older than 70. <583 pg/mL in 
premenopausal women and < 1008 pg/mL in postmenopausal women
Osteocalcin; ELISA, DIASource Diagnostics, Belgium, Ref. range: 5–25 ng/mL









1 77 2b/Mn Primary Risedronate 2 60 1.6 1.6
2 89 2/Mn Primary Alendronate 1 N/A N/A N/A
3 88 3/Mx Secondary to hypogonadismc Alendronate 10 70 0 0
4 66 2/Mn Primary Alendronate 1 80 0.97 11
5 68 2/Mn Primary Alendronate 1.5 60 1.6 N/A
6 67 2a/Mx Primary Alendronate 4 70 1.4 11.9
7 87 2b/Mn Primary Risedronate 3 60 3.5 3.5
8 77 2/Mn Primary Alendronate 3 165 5.06 6.7
9 71 2b/Mn Primary Alendronate 3 112 0.5 0.5
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the indication of BP in BRONJ patients seems to be quite 
different across Asian countries (Urade et  al. 2011; Lee 
et al. 2013) and western countries (Lazarovici et al. 2009; 
Otto et al. 2011; Walter et al. 2014), we found a clinical 
disparity between the 2 continents as well. BRONJ and 
atypical femur fracture (Shane et  al. 2014) are the most 
frustrating complications of long-term BPs. According 
to a gender difference study of bisphosphonates-related 
complications, female gender has been thought to be 
a risk factor for atypical femur fractures but there was 
no significant gender difference for the development of 
BRONJ (Kharazmi et al. 2014).
Vitamin D and calcium supplements are recommended 
for the maintenance of bone mineral mass although con-
flicting data on the benefit still exist. One of the main 
secondary causes of osteoporosis in males is low calcium 
intake and vitamin D deficiency. In this study, the serum 
vitamin D level was quite lower than 30  ng/mL, which 
might cause impairment in bone remodeling, and failure 
to control osteoclastogenesis (Baldock et al. 2006). There-
fore such conditions may precipitate osteoporosis, and 
vitamin D deficiency might be a risk factor for BRONJ as 
well.
Testosterone prevents bone loss and may increase bone 
mass in hypogonadism, although evidence is still lacking 
in long-term usage. In spite of the beneficial effect of tes-
tosterone on bone mass, ordinary osteoporosis therapeu-
tics are usually selected (Boonen et al. 1997).
Several medications including BPs are believed to 
have a positive effect on BMD in the extreme event of 
hypogonadism due to chemical castration like one of 
the cases in the study (Smith 2007). It seems only rea-
sonable to use BPs to prevent bone loss in men receiv-
ing androgen deprivation therapy. In prostate cancer 
patients, BP administration for these patients is quite 
well known even to general dentists, so specific history 
taking for BP intake is usually made. However, besides 
prostate cancer, other conditions inducing hypognoad-
ism such as total orchiectomy and chemotherapy can 
also lead to osteoporosis and may increase the risk of 
BRONJ.
In very old age and hypogonadal conditions, BPs may 
be given to males in a long-term manner. Therefore, cli-
nicians should ask patients if they have ever taken BP 
therapy regardless of their gender. Dental professions 
should be aware that male patients may be on BP ther-
apy besides oncologic reasons therefore proper commu-
nication and referral should be established between the 
professions.
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